Accepted for/Published in: JMIR Research Protocols
Date Submitted: Sep 25, 2025
Date Accepted: Mar 11, 2026
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Real-world effects of Liuwei Dihuang pill for menopausal syndrome:study protocol for a prospective,observational,multicenter cohort
ABSTRACT
Background:
Background:
Liuwei Dihuang (LWDH) pill, an adaptation of Chinese herbal medicine, is commonly employed to alleviate menopausal symptoms. Experimental and randomized controlled trials indicated that LWDH pill was advantageous for patients with menopausal syndrome (MPS). However, the pertinent scientific evidence of LWDH in the real clinical practice remains insufficient.To systematically evaluate the effectiveness and safety of LWDH pill in the treatment of MPS under real-world clinical conditions, thereby providing high-quality evidence for rational clinical use.
Objective:
Objective:
To systematically evaluate the effectiveness and safety of LWDH pill in the treatment of MPS under real-world clinical conditions, thereby providing high-quality evidence for rational clinical use.
Methods:
Methods:
This prospective, multicenter, real-world, observational cohort study will be performed at six designated centers in China from March 9,2025 to Septemper 30,2025. A total of 1000 patients with menopausal syndrome will be allocated to either the exposure group (patients receiving LWDH treatment) or the non-exposed group (patients not receiving LWDH treatment), mostly based on patient desire in a genuine clinical setting. The main observation indicators will be changes in the modified kupperman scale and sex hormone levels.The secondary outcomes encompass alterations in the Menopausal quality of life scale, improvement in TCM syndrome scale, and variations in blood glucose and lipid levels.In addition, the multi-omics integrated analysis technique is employed to explore the potential mechanisms of action. Adverse events or clinically significant abnormalities in vital signs and laboratory parameters, irrespective of severity, will be documents during the trial to evaluated the safety of LWDH. Assessments will be performed at baseline, 2 weeks and 4 weeks after enrollment,with a subsequent 2-week follow-up. Data will be analyzed using a combination of artificial intelligence and traditional statistical methods.
Results:
Results:
This study will, for the first time, systematically evaluate the clinical efficacy and safety of LWDH under real-world conditions, and quantitatively assess improvements in menopausal syndrome using multiple outcome measures.
Conclusions:
Conclusion: This real-world cohort study is expected to provide important evidence regarding the clinical efficacy and safety of LWDH in treating menopausal syndrome, offering a scientific basis for its standardized use in clinical practice.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.